An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Eli Lilly says a new analysis shows its diabetes pill, Foundayo, has an edge over Novo Nordisk’s oral version of Ozempic when it comes to controlling blood sugar. The claim comes from Lilly’s presentation of data comparing the two drugs’ effects in people with type 2 diabetes. Reuters reported the companies’ competing messages, so this is a company-released comparison rather than an independent, definitive verdict. Foundayo is Lilly’s brand name for tirzepatide taken by mouth. It’s part of a class of drugs that act like certain gut hormones that help lower blood sugar and reduce appetite. In simple terms: these pills are designed to mimic signals your body uses after eating to help control blood sugar and, as a side effect, can help with weight loss. Novo’s oral Ozempic is semaglutide in pill form, which works in a similar way by copying a single gut hormone signal. What Lilly presented is a head-to-head analysis suggesting Foundayo lowered average blood sugar more than the oral semaglutide in the studied group. The important detail is how the comparison was made. Reuters frames this as company-reported results, so the analysis may use selected data or methods that favor one drug. The report doesn’t say this was a large independent trial directly comparing the two medicines in the same study population under identical conditions, which is the strongest kind of evidence. So while the numbers Lilly shared may look promising, they don’t necessarily settle which drug is better for everyone. Why this matters is practical: both drugs are alternatives to injectable diabetes medicines and to older pills. If one oral option consistently controls blood sugar better, it could change what doctors prescribe, especially for people who dislike injections. Better blood-sugar control lowers the risk of long-term diabetes complications like nerve, eye, and kidney damage. Patients, insurers, and doctors watch these comparisons closely because small differences in effect, side effects, cost, and convenience can influence real-world choices. There are important caveats. Company comparisons can be biased by which studies or patient groups they choose, and Reuters’ summary suggests this is a competitive claim rather than a regulator-verified finding. Side effects for these medicines often include nausea, stomach upset, and possible weight loss; rare but serious risks have been discussed for this class of drugs. Regulatory approvals, exact dosing, and long-term safety profiles can differ between products and formulations. People should not switch medications based on a press claim; decisions should be made with a healthcare provider who can consider personal health history. Bottom line: Lilly says its oral tirzepatide pill outperformed Novo’s oral semaglutide in a company analysis, but the claim needs cautious interpretation and confirmation from independent or head-to-head trials before changing care.
Source: Reuters